Richtig G, Wolf M, Schulter G, et al. Body-Mass-Index as a predictive marker for response in patients with metastatic melanoma treated with ipilimumab. SMR 2017, P01-15.
Neoadjuvant pertuzumab plus trastuzumab met of zonder chemotherapie: 5-jaarsoverlevingsdata
jun 2022 | Borstkanker